|
46
|
JW Pharmaceutical Collaborates with U.S.-Based Tempus AI to Develop Anti-Cancer Drugs Using Clinical Data and Organoids |
2024-10-29 |
|
45
|
JW Pharmaceutical Accelerates Development of Innovative Drugs with AI-Based R&D Integrated Platform ‘JWave’ |
2024-08-27 |
|
44
|
JW Pharmaceutical Collaborates with Zebit to Develop Metabolic Disease Drugs Using Zebrafish as an Alternative Model |
2024-07-10 |
|
43
|
JW Pharmaceutical’s C&C Research Laboratories Selected for National New Drug Development Project for Prostate Cancer Treatment |
2024-06-25 |
|
42
|
JW Pharmaceutical Receives IND Approval for STAT3-Targeted Anticancer Drug ‘JW2286’ |
2024-06-19 |
|
41
|
JW Pharmaceutical Demonstrates Superior Hair Follicle Formation and Hair Growth of ‘JW0061’ Compared to Existing Hair Loss Treatments |
2024-05-20 |
|
40
|
JW Pharmaceutical Presents Preclinical Results for Hair Loss Treatment ‘JW0061’ at the Society of Investigative Dermatology |
2024-05-07 |
|
39
|
JW Pharmaceutical, U.S. DSMB Recommends Continuation of Global Phase 3 Trial for Gout Treatment 'Epaminurad' |
2024-02-14 |
|
38
|
JW Pharmaceutical's Gout Treatment 'Epaminurad' Receives Phase 3 Clinical Trial Approval in Malaysia |
2024-01-15 |
|
37
|
C&C Research Laboratories and XtalPi Announce Collaborative Research Agreement for STAT6-Targeted Small Molecule Therapeutics |
2023-12-18 |